Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimizing clinical and organizational practice in cancer survivor transitions between specialized oncology and primary care teams: a realist evaluation of multiple case studies.
Tremblay D, Prady C, Bilodeau K, Touati N, Chouinard MC, Fortin M, Gaboury I, Rodrigue J, L'Italien MF. Tremblay D, et al. Among authors: prady c. BMC Health Serv Res. 2017 Dec 16;17(1):834. doi: 10.1186/s12913-017-2785-z. BMC Health Serv Res. 2017. PMID: 29246224 Free PMC article.
Collaborative governance in the Quebec Cancer Network: a realist evaluation of emerging mechanisms of institutionalization, multi-level governance, and value creation using a longitudinal multiple case study design.
Tremblay D, Touati N, Poder T, Vasiliadis HM, Bilodeau K, Berbiche D, Denis JL, Pomey MP, Hébert J, Roch G, Prady C, Lévesque L. Tremblay D, et al. Among authors: prady c. BMC Health Serv Res. 2019 Oct 25;19(1):752. doi: 10.1186/s12913-019-4586-z. BMC Health Serv Res. 2019. PMID: 31653231 Free PMC article.
Building resilience in oncology teams: Protocol for a realist evaluation of multiple cases.
Tremblay D, Touati N, Kilpatrick K, Durand MJ, Turcotte A, Prady C, Poder TG, Richard PO, Soldera S, Berbiche D, Généreux M, Roy M, Laflamme B, Lessard S, Landry M, Giordano É. Tremblay D, et al. Among authors: prady c. PLoS One. 2022 May 12;17(5):e0268393. doi: 10.1371/journal.pone.0268393. eCollection 2022. PLoS One. 2022. PMID: 35551336 Free PMC article.
Real-world patient- and caregiver-reported outcomes in advanced breast cancer.
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J. Lambert-Obry V, et al. Among authors: prady c. Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14. Curr Oncol. 2018. PMID: 30111973 Free PMC article.
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M. Martel S, et al. Among authors: prady c. Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Cancer Treat Rev. 2018. PMID: 29108713 Review.
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A. Bachelot T, et al. Among authors: prady c. BMC Cancer. 2014 Mar 7;14:166. doi: 10.1186/1471-2407-14-166. BMC Cancer. 2014. PMID: 24606768 Free PMC article. Clinical Trial.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
21 results